Hormonal
GLP-1 receptor agonists (e.g., Semaglutide) are effective for weight loss and metabolic stabilization but cause significant weight regain (rebound) upon discontinuation, necessitating long-term management or transition to surgery.
GLP-1 medications like Semaglutide are powerful tools for weight loss and fixing metabolic issues, but they are not a one-time cure. If you stop taking them, you will likely regain most of the weight. Use them to stabilize your health and weight before considering skin removal surgery, or commit to long-term use if surgery is not an option.
Дані багатоцентрового дослідження STEP 4 свідчать, що після припинення введення семаглутіду пацієнти... протягом року відновили до двох третин втраченої маси тіла. Це вказує на те, що ефект препарату є значною мірою оборотним...
Why this rating
Cites specific multi-center trial data (STEP 4).
Source
Comprehensive approach to the treatment of patients with aesthetic deformity of the anterior abdominal wall with concomitant metabolic disorders
Todurov et al. · Diabetes Obesity Metabolic Syndrome · 2025
DOI 10.57105/2415-7252-2025-4-03
More from this paper
- Bariatric surgery (Roux-en-Y or Sleeve Gastrectomy) provides superior long-term weight loss and metabolic remission compared to conservative lifestyle interventions alone.Strong
- Performing bariatric surgery (Roux-en-Y or sleeve gastrectomy) prior to abdominoplasty significantly reduces postoperative complications and improves long-term stability compared to abdominoplasty alone in patients with metabolic syndrome.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →